A Study of Pyrotinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in Patients With HER2+Metastatic Breast Cancer Who Have Prior Received Anthracyclin, Taxane or Trastuzumab

Clinical trial NCT02422199 · UNKNOWN

Trial details

NCT number: NCT02422199
Sponsor: Jiangsu HengRui Medicine Co., Ltd.
Status: UNKNOWN
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

HER2 Positive Metastatic Breast Cancer

Start date: 2015-05-01
Primary completion: 2016-10-01
Enrollment: 128

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.